WO2007097991A3 - Methods and kits for dosing of antiviral agents - Google Patents
Methods and kits for dosing of antiviral agents Download PDFInfo
- Publication number
- WO2007097991A3 WO2007097991A3 PCT/US2007/004003 US2007004003W WO2007097991A3 WO 2007097991 A3 WO2007097991 A3 WO 2007097991A3 US 2007004003 W US2007004003 W US 2007004003W WO 2007097991 A3 WO2007097991 A3 WO 2007097991A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosing
- methods
- kits
- antiviral agents
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is directed to methods and pharmaceutical kits for dosing a patient with antiviral nucleosides in an alternating manner.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77399706P | 2006-02-16 | 2006-02-16 | |
| US60/773,997 | 2006-02-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2007097991A2 WO2007097991A2 (en) | 2007-08-30 |
| WO2007097991A3 true WO2007097991A3 (en) | 2008-06-12 |
Family
ID=38437868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2007/004003 Ceased WO2007097991A2 (en) | 2006-02-16 | 2007-02-15 | Methods and kits for dosing of antiviral agents |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2007097991A2 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP3237A (en) | 2008-04-23 | 2015-04-30 | Gilead Sciences Inc | 1'-Substituted carba-nucleoside analogs for antiviral treatment |
| HRP20130862T1 (en) | 2009-09-21 | 2013-10-25 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs |
| US9090642B2 (en) | 2010-07-19 | 2015-07-28 | Gilead Sciences, Inc. | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| SI2595980T1 (en) | 2010-07-22 | 2014-11-28 | Gilead Sciences, Inc. | Methods and compounds for treating paramyxoviridae virus infections |
| TWI740546B (en) | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | Methods for the preparation of ribosides |
| LT3785717T (en) | 2015-09-16 | 2022-04-11 | Gilead Sciences, Inc. | TREATMENTS FOR CORONAVIRIDAE INFECTIONS |
| CN110869028B (en) | 2017-03-14 | 2023-01-20 | 吉利德科学公司 | Method of treating feline coronavirus infection |
| CA3178212A1 (en) | 2017-05-01 | 2018-11-08 | Gilead Sciences, Inc. | Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| EP3651734B1 (en) | 2017-07-11 | 2024-11-13 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| AU2021214911A1 (en) | 2020-01-27 | 2022-07-21 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
| CA3169340A1 (en) | 2020-03-12 | 2021-09-16 | Pavel R. Badalov | Methods of preparing 1'-cyano nucleosides |
| WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| CA3179226A1 (en) | 2020-05-29 | 2021-12-02 | Tomas Cihlar | Remdesivir treatment methods |
| PE20230618A1 (en) | 2020-06-24 | 2023-04-14 | Gilead Sciences Inc | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF |
| DK4204421T3 (en) | 2020-08-27 | 2024-05-27 | Gilead Sciences Inc | Compounds and methods for treating viral infections |
| CN114010590B (en) * | 2021-11-24 | 2023-12-01 | 华东师范大学 | A kind of nucleoside antiviral drug gel and its preparation method and application |
| TWI867455B (en) | 2022-03-02 | 2024-12-21 | 美商基利科學股份有限公司 | Compounds and methods for treatment of viral infections |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
-
2007
- 2007-02-15 WO PCT/US2007/004003 patent/WO2007097991A2/en not_active Ceased
Non-Patent Citations (2)
| Title |
|---|
| PRUVOST ET AL.: "Measurement of Intracellular Didanosine...", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 49, no. 5, 2005, pages 1907 - 1914 * |
| RAY ET AL.: "Role of Purine Nucleoside Phosphorylase Interactions between 2',3'-Dideoxyinosine and Allopurinol, Ganciclovir, or Tenofovir", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 48, no. 4, 2004, pages 1089 - 1095, XP008037415, DOI: doi:10.1128/AAC.48.4.1089-1095.2004 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007097991A2 (en) | 2007-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007097991A3 (en) | Methods and kits for dosing of antiviral agents | |
| ZA201000075B (en) | Purin derivatives for use in the treatment of fab-related diseases | |
| IL199151A (en) | Pyrimidine derivatives, pharmaceutical compositions comprising them, their use in the treatment of cancer and kits comprising them | |
| IL195244A0 (en) | Inhibitors of human immunodeficiency virus replication | |
| IL210802A0 (en) | Purin derivatives for use in the treatment of fab-related diseases | |
| IL195731A0 (en) | Pyrimidine derivatives useful in the treatment of cancer | |
| CA119744S (en) | Bottle | |
| IL194865A (en) | Haloaryl substituted aminopurines and use thereof | |
| EP2220046A4 (en) | INHIBITORS OF THE REPLICATION OF THE HUMAN IMMUNODEFICIENCY VIRUS | |
| EP2220095A4 (en) | INHIBITORS OF THE REPLICATION OF THE HUMAN IMMUNODEFICIENCY VIRUS | |
| EP2220076A4 (en) | INHIBITORS OF THE REPLICATION OF THE HUMAN IMMUNODEFICIENCY VIRUS | |
| EP2220084A4 (en) | INHIBITORS OF THE REPLICATION OF THE HUMAN IMMUNODEFICIENCY VIRUS | |
| SI2069342T1 (en) | 2-ARYL-6-PHENYLIMIDAZO?á1,2-A?åPYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | |
| IL195821A0 (en) | Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors | |
| ZA200809911B (en) | Disposable article with serviceable indicia | |
| IL193693A0 (en) | Purine compounds and methods of use thereof | |
| ZA200808754B (en) | Tetrahydronaphthaline derivatives, methods for the production and use hereof as anti-inflammatory agents | |
| IL198481A0 (en) | Pyrrole derivatives, preparation use of the same in therapy | |
| ZA201108106B (en) | Use of phthalimide derivatives in the treatment of diseases | |
| PL2084272T3 (en) | Clonation, expression and use of acid lysophospholipases | |
| BRPI0719997A2 (en) | EPOTILONE USE IN THE TREATMENT OF OSTEOPOROSIS AND RELATED DISEASES | |
| NO20080740L (en) | Heterocyclylamide-substituted thiazoles, pyrroles and thiophenes | |
| AU311456S (en) | Cycle mudguard | |
| AU311455S (en) | Cycle mudguard | |
| ZA200810524B (en) | Pyrimidine derivatives useful in the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07750815 Country of ref document: EP Kind code of ref document: A2 |